Announcements
- Cara Therapeutics Announces Exploration of Strategic Alternatives
- Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
- Cara Therapeutics Reports First Quarter 2024 Financial Results
- Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
- Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
- Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
- Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
- Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
- Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
More ▼
Key statistics
On Friday, Cara Therapeutics Inc (69C:MUN) closed at 0.3082, 17.28% above the 52 week low of 0.2628 set on Jun 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3082 |
---|---|
High | 0.3082 |
Low | 0.3082 |
Bid | 0.3376 |
Offer | 0.3464 |
Previous close | 0.3082 |
Average volume | 1.14k |
---|---|
Shares outstanding | 54.68m |
Free float | 46.34m |
P/E (TTM) | -- |
Market cap | 20.36m USD |
EPS (TTM) | -2.26 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 07:02 BST.
More ▼